Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't think they have - been looking around but not able to find any info.
Thanks.
Hi Matt - Are you still holding HTM and planing to hold?
Great call Matt and great Board!!!!
River of money will flow from biotech to these hot sectors: strategist
http://blogs.marketwatch.com/thetell/2014/03/25/river-of-money-will-flow-from-biotech-to-these-hot-sectors-strategist/
Thanks. Holding here as well.
Hi Matt - Are you holding HTM through ER? Thanks!
From MSTX 7th Annual OneMedForum Emerging Company Finance Conference
http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_01.14.2014.pdf
Look at page 7 and 26:
Open First EPIC Site Outside the U.S. Q1 ’14
Report Biomarker Data from Heart Failure Study Q1 ’14
Initiate Phase 2 Study in Acute Limb Ischemia Q1 ’14
Outcome from U.S. Adopted Names Council Review of Unique Designation for Purified Poloxamer 188 Q1 ’14
Provide Details of Heart Failure Study at Major Medical Conference Q2 ’14
Request Orphan Designation for ALI in EU (Received in U.S.) Q2 ‘14
Announce Clinical Development Strategy in Heart Failure Q2 ’14
Initiate Nonclinical POC Study in Resuscitation Q2 '14
Initiating ALI Phase 2 should come out next week or 1st Quarter of 2014.
This guy is awesome!!!! Follow him if you like.
roberto pedone ?@zerosum24 7m
$MSTX looking ready to make a move.. Next biotech to have on radar http://stockcharts.com/h-sc/ui?s=MSTX&p=D&yr=0&mn=6&dy=0&id=p52723598742 …
Hi AF. You still have HUSA? Any comments on ACST?
http://scharts.co/PRGcyk
Video on HTM and others....
http://milestonecapitalgrowthportfolio.com/video/160/
Maybe he/she desperate for attention? Borderline suicidal?
Why don't you sell and move on and why do you torture yourself like this? Is there anything that we can do to make you feel better?
Is not gonna go down to .60. This is micro biotech - there's no 'earnings'.
Good job. Yes, we will find out Monday or Sunday evening.
Yes. See below. Still have all of my THM and added more on Friday for GSS as well.
Moscow has been tightening its military grip on the Crimean peninsula, and the pro-Russian authorities there have called a 16 March referendum to secede from Ukraine and join Russia.
http://www.bbc.com/news/world-europe-26501716
My company is 2 minutes (driving) from MSTX. Have heard good things about them. Past is the past.
Keep in mind that Jack Lief is their CoB, who is also CEO of ARNA. I do see $1.50 by end of month. Where are you in Asia? I'm thinking about moving Bali to live, trade, and surf.
Copied it from Twitter. That is from Mast themselves.
Starting next week......
Going into #RareDiseaseDay on Feb 28, @MastThera will be posting new videos each day next wk from our annual #sicklecell conference. $MSTX
THM up in PM.
International Tower Hill Mines Ltd Pre-Market Trading
THM
$.74
*
0.09
negative
13.85% Get THM Alerts
Read more: http://www.nasdaq.com/symbol/thm/premarket#ixzz2tmBOMCjp
Beautiful!!!!
Where are you in Europe?
Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
- Statistically significant and durable reductions in troponin and NT-proBNP
- Minimal effect on heart rate and vascular resistance
- Potentially novel mechanistic approach to treatment of heart failure
http://finance.yahoo.com/news/mast-therapeutics-provides-additional-results-130000152.html
Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
- Statistically significant and durable reductions in troponin and NT-proBNP
- Minimal effect on heart rate and vascular resistance
- Potentially novel mechanistic approach to treatment of heart failure
http://finance.yahoo.com/news/mast-therapeutics-provides-additional-results-130000152.html
A Vista Partners’ Commentary “Interview with Mast Therapeutics’ (MSTX) CEO Brian Culley Regarding FDA’s Recent Public Meeting “Patient-Focused Drug Development for Sickle Cell Disease” - See more at: http://www.vistapglobal.com/2014/02/mstx/#sthash.TCyMccqf.8dOX3d7d.dpuf
Date
Hi
Lo
Total Volume
Short Volume
% Short Vol
Date Hi Lo Total Volume Short Volume % Short Vol
Wed, Feb 12, 2014 0.88 0.8139 2193711 357486 17%
Tue, Feb 11, 2014 0.8473 0.8 3143054 133002 5%
Mon, Feb 10, 2014 0.91 0.83 3778036 358150 10%
Fri, Feb 7, 2014 0.859 0.8155 1813038 306376 17%
Thu, Feb 6, 2014 0.8489 0.8002 1223289 323954 27%
Wed, Feb 5, 2014 0.865 0.81 1071790 204467 20%
Tue, Feb 4, 2014 0.879 0.77 3223901 545519 17%
Mon, Feb 3, 2014 0.91 0.82 2499899 166727 7%
Fri, Jan 31, 2014 0.92 0.835 3520339 817375 24%
Thu, Jan 30, 2014 0.88 0.81 1886106 200491 11%
Wed, Jan 29, 2014 0.8516 0.8 2736041 274382 11%
Tue, Jan 28, 2014 0.9337 0.8353 3195246 491403 10%
Mon, Jan 27, 2014 0.9898 0.82 7062702 665588 5%
Fri, Jan 24, 2014 1.03 0.926 5425408 498838 7%
Thu, Jan 23, 2014 1.06 0.92 7481191 803309 8%
Aires is expected to contribute approximately $3 million of net cash at the closing of the merger, so, as currently contemplated, our first year of development of AIR001 will not require additional capital investment by Mast," Mr. Culley concluded.
Here's the Conf. Call this morning.
http://www.masttherapeutics.com/investors/events/
Good time to get in, picked up 20K shares @ .84.
Mast Therapeutics Inc (NYSEMKT:MSTX) Amends The Entry Criteria
Boston, MA – (NYSEPOST) – 02/07/2014 – Last month, Mast Therapeutics Inc (NYSEMKT:MSTX) provided its update on status of EPIC, the company’s pivotal phase III study of its MST-188 in the treatment of sickle cell disease. Consistent with its prior guidance, Mast Therapeutics Inc (NYSEMKT:MSTX) announced that 40 different clinical sites had been opened in the United States by 2013 year end. In addition, the clinical sites are now expected to open in a minimum of 3 countries outside the United States in the 2014 Q1. This will lead to almost a total of around 30 ex-U.S. sites that will be opened up by 2014 end.
The overall study -enrollment is consistent and in-line with its internal projections and Mast Therapeutics Inc (NYSEMKT:MSTX) affirmed its earlier guidance that it projects to complete the full enrollment for this trial by 2015-end. Mast Therapeutics Inc (NYSEMKT:MSTX)’s Chief Executive Officer, Brian M. Culley said that they are pleased to see an early enrollment for the EPIC proceeding which is line with the company’s projections. Now that this enrollment is right on track and with the $44M on the company’s balance sheet to start 2014, they continue seeing MST-188 well-positioned to become the 1st drug in the treatment of an ongoing vaso-occlusive-crisis in patients suffering from sickle cell disease.
Considering that there are just very limited comprehensive sickle cell centers that have the infrastructure that is required to conduct a clinical-study, they believe that the company’s ability to quickly establish EPIC at the 40 sites is a reflection of the strong interest in this study amongst the physicians who treat the patients. To a certain degree, this is attributed to the enthusiasm that is shown by physicians, towards this study as well as identification of eligible adult patient candidates, Mast Therapeutics Inc (NYSEMKT:MSTX) has also decided to amend the entry criteria of the study and will expand the age-range and the genotype.
Experimental compound to restore microvascular function in blood disorders
Phase 3 Clinical Trial for Sickle Cell Disease: Betty Pace, MD, received a $178K, 2-year award from Mast Therapeutics, Inc. for “MST-188-01: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double blind, Placebo-Controlled Multicenter Trial of MST-188.”
The EPIC study will test an experimental compound called MST-188, which is designed to restore microvascular function that is compromised in a number of diseases, including sickle cell disease (SCD). Specifically, the EPIC study will evaluate whether MST-188 can reduce 1) the duration of vaso-occlusive crisis (VOC) in subjects with SCD, and 2) the frequency of re-hospitalization due to a recurrence of VOC. EPIC will also investigate the development of acute chest syndrome during VOC in subjects who receive MST-188. The study officially opened at GRU on November 1, 2013 and will enroll nearly 400 individuals aged 8-17 with sickle cell anemia from participating academic centers across the United States through December 2015.
http://fscdr.org/Pace
Won't be too long.....
--Provided U.S. Food and Drug Administration (FDA), on November 19, 2013,
with additional information requested in support of DARA's request for
orphan drug designation for the Company's Phase 2 development asset,
KRN5500, for the treatment of painful, treatment-refractory, chronic
chemotherapy-induced peripheral neuropathy ("CCIPN").